Practo describes Srijesh Kumar’s appointment as Global Chief Technology and Product Officer as a ‘strategic move’ ahead of its IPO, but the company remains silent on actual public offering timelines or technology leadership gaps that this hire addresses.
Kumar joins from consulting firm Kearney, where he led digital transformation initiatives. The appointment follows what Practo calls ‘sustained growth momentum’ in its healthcare platform business. The company operates across multiple geographies with technology infrastructure supporting telehealth, clinic management software, and health records systems.
Practo’s framing creates an interesting governance puzzle. The company positions this as IPO preparation, suggesting current technology leadership needed reinforcement. But the announcement provides no details about Kumar’s reporting structure, technology budget authority, or integration with existing product development teams.
The timing suggests technology governance concerns ahead of public market scrutiny. IPO-bound companies typically strengthen C-suite teams when current leadership cannot credibly present to institutional investors or when due diligence reveals capability gaps. Practo’s decision to create a combined technology and product role indicates either consolidation of previously separate functions or recognition that technology strategy needed unified oversight.
Kumar’s consulting background raises execution questions that boards evaluating similar appointments should consider. Consulting firms excel at technology strategy and digital transformation frameworks. But running day-to-day technology operations at a scaled healthcare platform requires different skills. The transition from advisory work to operational leadership often reveals capability gaps that initial interviews miss.
What remains unclear is Practo’s actual IPO readiness timeline. Companies often use ‘IPO preparation’ as a catch-all explanation for senior hires, even when public offering plans are speculative or distant. Real IPO preparation involves specific regulatory compliance, financial reporting upgrades, and governance structure changes that have defined timelines.
Healthcare technology companies face additional complexity in public markets. Investors scrutinise patient data handling, regulatory compliance across jurisdictions, and technology scalability under regulatory constraints. A Global CPTO role suggests Practo operates across multiple regulatory environments, but the announcement provides no insight into how this appointment addresses jurisdiction-specific compliance requirements.
My Boardroom Takeaway: When evaluating senior technology appointments ahead of IPO plans, boards should require clear documentation of capability gaps being addressed and specific timeline commitments for public offering preparation. A ‘strategic’ hire without defined success metrics or reporting structure often signals reactive rather than strategic planning. Directors may wish to verify that new technology leadership roles have appropriate budgetary authority and decision-making scope to justify their C-suite positioning, particularly when IPO-readiness claims lack supporting detail.